January 1, 2003European Journal of Heart Failure
Pharmacotherapeutic Approaches for Decompensated Heart Failure: A Role for the Calcium Sensitiser, Levosimendan?
Why the study?
Does levosimendan improve haemodynamics and symptoms without increasing oxygen consumption in patients with decompensated heart failure?
Population
Patients hospitalised with decompensated heart failure
Comparison
Calcium sensitisers, specifically levosimendan vs Traditional positive inotropic agents
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May support levosimendan for haemodynamic relief in decompensated HF; hypothesis-generating, needs RCTs before practice change.
Structured PICO
Does levosimendan improve haemodynamics and symptoms without increasing oxygen consumption in patients with decompensated heart failure?
P
Population
Patients hospitalised with decompensated heart failure
I
Intervention
Calcium sensitisers, specifically levosimendan
C
Comparator
Traditional positive inotropic agents (discussed conceptually)
O
Outcome
Symptomatic and haemodynamic improvement
Levosimendan emerges as a promising treatment for decompensated heart failure by enhancing cardiac performance without the deleterious effects on oxygen consumption seen with traditional inotropes.
Cite This Study
Greenberg et al. (2003) studied this question.